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Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, known to involve different organs including the heart. One of the
common cardiac manifestations is pericarditis [1]. Other forms of cardiac
involvement include coronary artery disease, arteritis and valvular disease. One of the rare presentations of systemic lupus erythematosus include myocarditis and once suspected, should be diagnosed and treated
promptly to avoid fatal consequences [2]. We report an interesting case
of a patient with a history of SLE presenting with cardiogenic shock from
acute myocarditis, requiring advanced heart failure therapies.
A 41-year-old Caucasian male with a history of SLE diagnosed 2 years
ago on treatment with hydroxychloroquine, presented to an outside
hospital with complains of worsening shortness of breath and fatigue
for 1 week. On initial assessment, significant findings on examination were mild confusion, jugular venous distention, crepitant rales
at bases of both the lungs, a grade 3/6 holo-systolic murmur heard
at the apex which radiated to the left axilla and cool extremities. His
heart rate was 112 beats per minute, blood pressure 98/62 mm Hg,
respiratory rate 29 breaths per minute, serum creatinine 1.7 mg/dl,
aspartate transaminase (AST) 4539 U/l, alanine transaminase (ALT)
4264 U/l, serum total bilirubin 1.5 mg/dl, international normalized ratio
(INR) 2.8 and serum lactate 5.4 mmol/l. Inotropic support with dobutamine was started. Two-dimensional echocardiography revealed severe
biventricular failure with global hypokinesis and left ventricular ejection
fraction of 15%. Left ventricle was dilated (6.3 cm) and an apical thrombus was present. Left heart catheterization demonstrated non-obstructive coronary artery disease. Right heart catheterization (RHC) on inotropic support showed a low output state, and an intra-aortic balloon pump
(IABP) was placed for mechanical circulatory support. He continued to
be in refractory cardiogenic shock and was transferred to Westchester
Medical Center for further therapy. On arrival to our facility, the patient
was hemodynamically unstable requiring multiple vasopressor agents
and IABP. He continued to have evidence of end organ malperfusion.
The decision was made to escalate mechanical circulatory support to
venous-arterial extracorporeal membrane oxygenation (V-A ECMO) as
a bridge to recovery or decision. Due to a high clinical suspicion for lupus
myocarditis, treatment with steroids, IVIG and Rituximab, was initiated.
Right heart catheterization on ECMO support showed a central venous
pressure of 9 mm Hg, a pulmonary artery (PA) pressure of 27/16 mm Hg
(mean: 20 mm Hg), a pulmonary capillary wedge pressure of 12, a PA sat-
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uration of 68%, cardiac output (Fick) of 8.5 l/min
and a cardiac index of 3.8 l/min/m2.
Endomyocardial biopsy showed no evidence of
significant interstitial mononuclear cell infiltration,
intracellular depositions or myocardial necrosis.
Trichome stain for amyloidosis was negative. The
serum ferritin level was normal, and the human
immunodeficiency virus antibody was negative.
A complete autoimmune work-up was pursued
including anti-double-stranded DNA antibody, anti-cardiolipin antibody, anti-Sjögren’s-syndrome-related antigen antibody, anti-Smith, anti-ribonucleoprotein antibody and lupus anticoagulant, which
were all undetectable. Serum antinuclear antibody
(ANA) was positive with a speckled pattern consistent with systemic lupus erythematosus.
Repeat assessment of the left ventricle function
by two-dimensional echocardiography showed
little improvement. End organ function including
liver enzymes and creatinine also improved. Attempts were made to wean off the ECMO support
which were unsuccessful. A heart mate II was implanted as a bridge to heart transplantation along
with tricuspid valve repair. No complications were
seen while the patient was on mechanical circulatory support. He survived to hospital discharge,
and two years later underwent an orthotopic
heart transplant without any post-operative complications.
Myocardial dysfunction in SLE is usually multifactorial and may result from immunological injury, ischemia, valvular disease, or coexisting problems such as hypertension. Although uncommon,
myocarditis is a serious manifestation of SLE, with
a clinical prevalence of about 9%. However, it has
been shown to be present in 57% of post mortem
analyses, suggesting a high prevalence of subclinical disease [3]. Myocarditis has a varied clinical
manifestation and can present with dyspnea,
non-exertional chest pain, peripheral edema, fever, orthopnea, diaphoresis, paroxysmal nocturnal
dyspnea, nausea, vomiting, or palpitations [4].
The gold standard for confirmation of myocarditis is endomyocardial biopsy. However, the focal
nature of the disease in lupus myocarditis makes
it less sensitive. The biopsy generally reveals
patches of myocardial fibrosis, sparse interstitial
mononuclear cell infiltrates, and occasional myocyte necrosis with immune complex deposition,
even in areas devoid of inflammatory changes.
The diagnosis is often achieved clinically and with
the use of diagnostic imaging. Echocardiography
and cardiac magnetic resonance imaging (MRI)
are commonly used to assess biventricular function [5]. Cardiac MRI can also detect the presence
of necrosis or scar in myocarditis by late gadolinium enhancement. Left ventricular dysfunction is
usually global, but can present as regional wall

motion abnormalities, chamber dilation or diastolic dysfunction [6, 7]. Part of the difficulty arising in
diagnosis of lupus myocarditis is that none of the
current diagnostic modalities have established
sensitivity or specificity. Management aspects of
the disease are also not well studied.
Myocarditis is a rare but fatal complication of
SLE. The relative rarity of the condition makes it
difficult to conduct controlled trials and various
managements have been described in isolated
case reports. High-dose corticosteroid treatment
is the most common therapy used for lupus
myocarditis [8, 9]. It appears to be an effective
initial treatment resulting in improvement of
left ventricular function in hemodynamically stable patient but there are very few cases of lupus
myocarditis presenting as cardiogenic shock requiring mechanical support. Other drugs used in
treatment are azathioprine, cyclophosphamide,
rituximab and intravenous immunoglobulins. Our
patient was treated with intravenous immunoglobulins, rituximab and glucocorticoids, which
resulted in little improvement of the left ventricle function. After undergoing orthotopic heart
transplantation, our patient showed no evidence
of recurrence of lupus myocarditis on subsequent
endomyocardial biopsies and imaging during
a follow-up of 24 months. The risk of recurrence
of lupus myocarditis in the transplanted heart has
not been established.
In conclusion, lupus myocarditis can present
as a life threatening complication. Its diagnosis is
primarily based on clinical suspicion as diagnostic
tools are not sensitive. Treatment is still not well
established. We describe a case of lupus myocarditis complicated by cardiogenic shock requiring
mechanical circulatory support.
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